Pay in 4 interest-free payments of $6.58 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
In February 2025, the National Medical Products Administration (NMPA) approved Innogens ultra-long-acting GLP-1 injection for type 2 diabetes, signaling growing government and regulatory support for GLP-1 innovation and boosting industry confidence
Manufacturer is cGMP / ISO 9001 / ISO 13485 compliant
Tirzepatide goes to $349.99/month or $249.99/month on a three-month plan, with bulk plan pricing that increases as your dose goes up
Our clinical experience extends to helping patients understand the lesser-known GLP-1 benefits that may improve their health outcomes
US$ 21.49
US$ 22.48
US$ 24.98
